Clinical Trials

100 enrolled

Phase 2 Not yet recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07269470 2025-12-16

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

40 enrolled

Phase 2/3 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

790 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03595917 2025-11-04

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Phase 1 Recruiting

40 enrolled

Burkitt Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05993949 2025-09-23

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

Phase 1 Active not recruiting

8 enrolled

Phase 1/2 Active not recruiting

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05192889 2025-09-22

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

35 enrolled 12 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05751044 2025-09-16

HEM-iSMART B

Phase 1/2 Recruiting

26 enrolled

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06855810 2025-08-26

CCCG-TALL-2025

Phase 2/3 Recruiting

610 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01990196 2025-08-17

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

45 enrolled

Genitourinary

Prostatic Neoplasms

NCT04838041 2025-07-30

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

51 enrolled

Phase 1 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02494882 2025-07-02

Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

12 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02420717 2025-06-08

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Phase 2 Terminated

11 enrolled 13 charts

Lymphoid

Burkitt Lymphoma

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1 Terminated

8 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT04925648 2025-05-15

PICASSO

22 enrolled

Genitourinary

Prostatic Neoplasms

NCT03560908 2025-05-01

Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

Phase 1 Withdrawn

Phase EARLY_PHASE1 Recruiting

Recurrence, Leukemia, Myeloid, Acute

NCT05432518 2025-04-25

Pilot Trial for Treatment of Recurrent Glioblastoma

10 enrolled

CNS

Glioblastoma, Recurrence

NCT03844360 2025-03-30

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Phase 4 Recruiting

1,500 enrolled

Hematologic Neoplasms

NCT01804985 2025-03-14

DESTINY

174 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03906292 2025-03-10

CMLXI

125 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00390793 2025-02-17

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

107 enrolled 11 charts

Blast Crisis, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01254864 2025-01-27

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

190 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT04164069 2024-12-27

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Phase 1 Completed

9 enrolled

Gastrointestinal

Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04147533 2024-11-26

HALF

150 enrolled

Substance Withdrawal Syndrome, Leukemia, Myeloid, Chronic-Phase

NCT05724329 2024-09-19

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02326311 2024-08-13

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Phase 3 Completed

229 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01471106 2024-07-10

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

26 enrolled 10 charts

Breast

Breast Neoplasms

NCT06355037 2024-07-08

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

10 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02954523 2024-07-05

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Phase 1/2 Terminated

10 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04115059 2024-03-21

Dasatinib In Waldenström Macroglobulinemia

Phase 1 Terminated

3 enrolled 13 charts

Lymphoid

Waldenstrom Macroglobulinemia

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02013648 2024-02-23

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

Phase 3 Completed

204 enrolled